2-Amino-6-chlor-5-methyl-pyrazin | 89182-16-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-Amino-6-chlor-5-methyl-pyrazin
• 英文别名: 6-chloro-5-methyl-pyrazin-2-ylamine；6-Chloro-5-methyl-2-pyrazinamine；6-chloro-5-methylpyrazin-2-amine
• CAS: 89182-16-1
• 化学式: C₅H₆ClN₃
• mdl: MFCD19208315
• 分子量: 143.576
• InChiKey: NRJMBXPWWYHDLC-UHFFFAOYSA-N

物化性质

• 沸点：
  276.9±35.0 °C(Predicted)
• 密度：
  1.349±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• IMIDAZOPYRAZINES AS LSD1 INHIBITORS
  申请人：Incyte Corporation

  公开号：US20160009720A1

  公开（公告）日：2016-01-14

  The present invention is directed to imidazo[1,2-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

  本发明涉及咪唑并[1,2-a]吡嗪衍生物，这些衍生物是LSD1抑制剂，可用于治疗癌症等疾病。
• IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS
  申请人：Incyte Corporation

  公开号：US20160009712A1

  公开（公告）日：2016-01-14

  The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

  本发明涉及咪唑并[1,5-a]吡啶和咪唑并[1,5-a]吡嗪衍生物，这些衍生物是LSD1抑制剂，在治疗癌症等疾病中有用。
• HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
  申请人：GiraFpharma LLC

  公开号：US20190023666A1

  公开（公告）日：2019-01-24

  Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

  提供了氨基吡嗪化合物作为腺苷受体的调节剂。这些化合物可能作为治疗经由G蛋白偶联受体信号通路介导的疾病的治疗剂，并且可能在肿瘤学中发挥特定作用。
• CONFORMATIONALLY RESTRICTED P13K AND MTOR INHIBITORS
  申请人：UNIVERSITAET BASEL

  公开号：US20160244463A1

  公开（公告）日：2016-08-25

  The invention relates to novel phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor compounds of formula (I) and (II), which are conformationally restricted, and for which the meaning of the substituents are listed in the description. Preferred compounds are those wherein X isoxygen, R 1 is morpholino and R 2 is substituted phenyl or heteroaryl. These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.

  本发明涉及一种新型的磷脂酰肌醇3-激酶（PI3K）和哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂化合物，其化学式为（I）和（II），分子构型受限，取代基含义详见说明书。优选的化合物是其中X为氧原子，R1为吗啉基，R2为取代苯基或杂环芳基。这些化合物可单独或与其他治疗剂联合使用，用于治疗由脂质激酶介导的疾病。
• PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES
  申请人：H. Lundbeck A/S

  公开号：EP3865484A1

  公开（公告）日：2021-08-18

  The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.

  本发明涉及 PDE9 抑制剂及其用于治疗良性前列腺增生症和镰状细胞病的用途。